Ullrich, R., L. Kracht, A. Brunn, K. Herholz, P. Frommolt, H. Miletic, M. Deckert, W.-D. Heiss and A. H. Jacobs: Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. In: Journal of Nuclear Medicine 50, 12, 1962-1968 (2009).

Ullrich, R., L. Kracht, A. Brunn, K. Herholz, P. Frommolt, H. Miletic, M. Deckert, W.-D. Heiss and A. H. Jacobs: Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. In: Journal of Nuclear Medicine 50, 12, 1962-1968 (2009).

Ullrich, R., L. Kracht, A. Brunn, K. Herholz, P. Frommolt, H. Miletic, M. Deckert, W.-D. Heiss and A. H. Jacobs: Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. In: Journal of Nuclear Medicine 50, 12, 1962-1968 (2009).

Sos, M. L., K. Michel, T. Zander, J. Weiss, P. Frommolt, M. Peifer, D. Li, R. Ullrich, M. Koker, F. Fischer, T. Shimamura, D. Rauh, C. Mermel, S. Fischer, I. Stückrath, S. Heynck, R. Beroukhim, W. Lin, W. Winckler, K. Shah, T. LaFramboise, W. F. Moriarty, M. Hanna, L. Tolosi, J. Rahnenführer, R. Verhaak, D. Chiang, G. Getz, M. Hellmich, J. Wolf, L. Girard, M. Peyton, B. A. Weir, T.-H. Chen, H. Greulich, J. Barretina, G. I. Shapiro, L. A. Garraway, A. F. Gazdar, J. D. Minna, M. Meyerson, K.-K. Wong and R. K. Thomas: Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. In: Journal of Clinical Investigation 119, 6, 1727-1740 (2009).

Sos, M. L., K. Michel, T. Zander, J. Weiss, P. Frommolt, M. Peifer, D. Li, R. Ullrich, M. Koker, F. Fischer, T. Shimamura, D. Rauh, C. Mermel, S. Fischer, I. Stückrath, S. Heynck, R. Beroukhim, W. Lin, W. Winckler, K. Shah, T. LaFramboise, W. F. Moriarty, M. Hanna, L. Tolosi, J. Rahnenführer, R. Verhaak, D. Chiang, G. Getz, M. Hellmich, J. Wolf, L. Girard, M. Peyton, B. A. Weir, T.-H. Chen, H. Greulich, J. Barretina, G. I. Shapiro, L. A. Garraway, A. F. Gazdar, J. D. Minna, M. Meyerson, K.-K. Wong and R. K. Thomas: Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. In: Journal of Clinical Investigation 119, 6, 1727-1740 (2009).

Sos, M. L., M. Koker, B. A. Weir, S. Heynck, R. Rabinovsky, T. Zander, J. M. Seeger, J. Weiss, F. Fischer, P. Frommolt, K. Michel, M. Peifer, C. Mermel, L. Girard, M. Peyton, A. F. Gazdar, J. D. Minna, L. A. Garraway, H. Kashkar, W. Pao, M. Meyerson and R. K. Thomas: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR. In: Cancer Research 69, 8, 3256-3261, Seq. No.: 1 (2009).

Sos, M., M. Koker, B. Weir, S. Heynck, R. Rabinovsky, T. Zander, J. M. Seeger, J. Weiss, F. Fischer, P. Frommolt, K. Michel, M. Peifer, C. Mermel, L. Girard, M. Peyton, A. F. Gazdar, J. D. Minna, L. A. Garraway, H. Kashkar, W. Pao, M. Meyerson and R. K. Thomas: PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. In: Cancer Research 69, 8, 3256-3261 (2009).

Frommolt, P. and R. K. Thomas: Standardized high-throughput evaluation of cell-based compound screens. In: BMC Bioinformatics 9, (2008).

Moler, I., K. Michel, N. Frech, M. Burger, D. Pfeifer, P. Frommolt, H. Veelken and A.-K. Thomas-Kaskel: Dendritic cell maturation with poly(I : C)-based versus PGE2-based cytokine combinations results in differential functional characteristics relevant to clinical application. In: Journal of Immunotherapy 31, 5, 506-519 (2008).

Frommolt, P. and R. K. Thomas: Standardized high-throughput evaluation of cell-based compound screens. In: BMC Bioinformatics 9, 1, 475-479, Seq. No.: 1 (2008).